{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-25-000018","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.474373+00:00","generated_at":"2026-05-22T22:58:10.449764+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance","bullets":["Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).","Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).","Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.","Company reaffirms 2025 full-year guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-25-000018","json":"https://secwatch.observer/filing/0001723128-25-000018.json","markdown":"https://secwatch.observer/filing/0001723128-25-000018.md","text":"https://secwatch.observer/filing/0001723128-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/0001723128-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000018/amrx-20250502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:58:10.449764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}